Study of Neoadjuvant Therapy Effects and Surgery Outcomes in Locally Advanced Thyroid Cancer Patients

What this Trial Is About

The trial studies patients with locally advanced thyroid cancer LATC, a form of thyroid cancer that invades nearby critical tissues and has a poor outlook. It evaluates the safety and effects of neoadjuvant therapy before surgery by analyzing imaging, biochemical, and pathological responses. Researchers also compare short-term surgical results and long-term outcomes with patients who have surgery upfront. The study further investigates immune cell changes and explores biological markers that may influence tumor resistance and treatment decisions. Participants receive neoadjuvant treatments such as multikinase inhibitors, RET inhibitors, BRAF b1 MEK inhibitors, or combinations including PD-1 inhibitors for at least two cycles before surgery. Others undergo immediate radical surgery based on expert team recommendations and patient choice. Tissue biopsies are performed for detailed tumor analysis. Surgery is done when patients are considered resectable either after therapy or at diagnosis. During the study, participants undergo imaging assessments, pathology evaluations at surgery, and biochemical tests up to a year after surgery. Researchers measure radiographic and pathologic responses, progression-free survival, surgical complication rates, and overall survival up to 24 months. The study includes monitoring for adverse events related to treatments and surgery, with data collected from multiple centers over several years.

Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer